Empowered Patient Podcast

Karen Jagoda
  • 4.9 (18)
  • Medicine
  • Updated Daily

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

  1. 2h ago ·  Bonus

    Harnessing Conversational AI to Reduce Healthcare Workflow Friction and Clinician Burnout with Peter Swimm Toilville TRANSCRIPT

    Peter Swimm, Founder of Toilville, is a conversational AI pioneer, and he describes the transformation in healthcare resulting from the use of AI and large language models to address clinician burnout and improve patient outcomes. He emphasizes that technology should adapt to practitioners' workflows rather than forcing practitioners to change their behavior. Human oversight is essential to ensure accuracy and transparency, and Peter advocates for a culture shift where time saved through the use of AI is reinvested in higher-quality patient care and clinician satisfaction. Peter explains, "I think a lot of people think of their problems as a unique snowflake in the world. I think if we boil the ocean down to its elements, it is an understanding of the system of its inhabitants. And so we do a lot of work with small businesses and clients who typically have worked for big companies, and they've chafed at all the rules and the boundaries and the problems. They leave the big company and want to run their own show, but they lose that infrastructure."   "A lot of times, they turn to tools like AI and automation, or they buy software products that don't entirely fit their thinking. And so we help them negotiate that pattern where the technology molds to what the presentation layer is and how you want to treat things and handle your data. And you don't change away from what your competitive advantage is, which is being a unique and talented person who runs the show the way they see best." "So I think the challenge is, don't let your FOMO be FAFO. Just because everyone's telling you to do AI and you don't really understand it and you don't see the positive outcomes, don't assume it's like a lack of training on your part." #SPELWork #Toilville #OptInPodcast #ResonantDiversification #AIGovernance #ResponsibleAI #ConsentFirst #DigitalHealth #HealthTech #HealthIT #ClinicalAI #HealthcareAI #PatientAdvocacy #ClinicianBurnout #HealthEquity #SDOH #AIAccountability #AIEthics #AISafety #ConsentFirst #DataSovereignty #HumanInTheLoop #HealthcareInnovation#DigitalHealth #PhysicianBurnout #HealthIT #ConversationalAI #PatientCare toilville.com Listen to the podcast here

  2. 2h ago

    Harnessing Conversational AI to Reduce Healthcare Workflow Friction and Clinician Burnout with Peter Swimm Toilville

    Peter Swimm, Founder of Toilville, is a conversational AI pioneer, and he describes the transformation in healthcare resulting from the use of AI and large language models to address clinician burnout and improve patient outcomes. He emphasizes that technology should adapt to practitioners' workflows rather than forcing practitioners to change their behavior. Human oversight is essential to ensure accuracy and transparency, and Peter advocates for a culture shift where time saved through the use of AI is reinvested in higher-quality patient care and clinician satisfaction. Peter explains, "I think a lot of people think of their problems as a unique snowflake in the world. I think if we boil the ocean down to its elements, it is an understanding of the system of its inhabitants. And so we do a lot of work with small businesses and clients who typically have worked for big companies, and they've chafed at all the rules and the boundaries and the problems. They leave the big company and want to run their own show, but they lose that infrastructure."   "A lot of times, they turn to tools like AI and automation, or they buy software products that don't entirely fit their thinking. And so we help them negotiate that pattern where the technology molds to what the presentation layer is and how you want to treat things and handle your data. And you don't change away from what your competitive advantage is, which is being a unique and talented person who runs the show the way they see best." "So I think the challenge is, don't let your FOMO be FAFO. Just because everyone's telling you to do AI and you don't really understand it and you don't see the positive outcomes, don't assume it's like a lack of training on your part." #SPELWork #Toilville #OptInPodcast #ResonantDiversification #AIGovernance #ResponsibleAI #ConsentFirst #DigitalHealth #HealthTech #HealthIT #ClinicalAI #HealthcareAI #PatientAdvocacy #ClinicianBurnout #HealthEquity #SDOH #AIAccountability #AIEthics #AISafety #ConsentFirst #DataSovereignty #HumanInTheLoop #HealthcareInnovation#DigitalHealth #PhysicianBurnout #HealthIT #ConversationalAI #PatientCare toilville.com Download the transcript here

    26 min

  3. 1d ago ·  Bonus

    Reformulating Diabetes Drug to Treat Degenerative Eye Diseases with Richard Garr Curative Biotechnology TRANSCRIPT

    Richard Garr, CEO and General Counsel of Curative Biotechnology, discusses the company's work in repurposing the diabetes drug metformin into an eye drop for degenerative eye diseases. The goal of the therapy is retinal preservation, aiming to slow or stop disease progression by acting at the cellular level in the back of the eye to protect it from damage, offering a non-invasive alternative to current treatments. Using a repurposed drug allows the company to build on well-documented safety data and reduces the size, cost and duration of clinical trials. Richard explains, "We are currently focused on repurposing the drug metformin, which is an FDA-approved drug that diabetics take. And as it turns out, we have reformulated it into an eye drop. This is licensed from the National Eye Institute. We have worldwide exclusive rights. The first patent in that estate was allowed about two months ago in Canada. We would expect it to be issued this summer. It's being prosecuted around the world." "We believe that it is a platform drug and that we'll be able to treat a wide range of degenerative eye diseases. It's repurposed because it is an approved FDA drug. It's been taken for decades orally by literally tens of millions of patients, mostly with type two diabetes. And really, the importance of that is that we know it's a safe systemically. So, everything you could want to know about the metformin systemically is known. What we have to show in our clinical trials is that it's safe in the eye and that it does, in fact, do what we suspect it does to treat degenerative eye disease." #CurativeBiotech #Ophthalmology #Retina #Neuroprotection #DryAMD #EyeCare #DrugRepurposing #Metformin #HealthcareInnovation #ClinicalResearch #CurativeBiotech CurativeBiotech.com Listen to the podcast here

  4. 1d ago

    Reformulating Diabetes Drug to Treat Degenerative Eye Diseases with Richard Garr Curative Biotechnology

    Richard Garr, CEO and General Counsel of Curative Biotechnology, discusses the company's work in repurposing the diabetes drug metformin into an eye drop for degenerative eye diseases. The goal of the therapy is retinal preservation, aiming to slow or stop disease progression by acting at the cellular level in the back of the eye to protect it from damage, offering a non-invasive alternative to current treatments. Using a repurposed drug allows the company to build on well-documented safety data and reduces the size, cost and duration of clinical trials. Richard explains, "We are currently focused on repurposing the drug metformin, which is an FDA-approved drug that diabetics take. And as it turns out, we have reformulated it into an eye drop. This is licensed from the National Eye Institute. We have worldwide exclusive rights. The first patent in that estate was allowed about two months ago in Canada. We would expect it to be issued this summer. It's being prosecuted around the world." "We believe that it is a platform drug and that we'll be able to treat a wide range of degenerative eye diseases. It's repurposed because it is an approved FDA drug. It's been taken for decades orally by literally tens of millions of patients, mostly with type two diabetes. And really, the importance of that is that we know it's a safe systemically. So, everything you could want to know about the metformin systemically is known. What we have to show in our clinical trials is that it's safe in the eye and that it does, in fact, do what we suspect it does to treat degenerative eye disease." #CurativeBiotech #Ophthalmology #Retina #Neuroprotection #DryAMD #EyeCare #DrugRepurposing #Metformin #HealthcareInnovation #ClinicalResearch #CurativeBiotech CurativeBiotech.com Download the transcript here

    22 min

  5. 6d ago ·  Bonus

    Immersive Precision Neurotherapy for Stroke and Parkinson's Rehabilitation with Zach Henderson MindMaze Therapeutics TRANSCRIPT

    Zach Henderson, CEO at MindMaze Therapeutics, has designed a precision neurotherapeutic solution designed to offer a scalable, engaging and immersive platform for patients recovering from strokes or managing Parkinson's disease. The solution is deployed across the entire care continuum from hospital to the patient's home, providing high-intensity therapy during the neuroplastic window. The emphasis is on augmenting therapists' care by equipping them with tools to encourage therapy adherence and with data to deliver precise, personalized care. Zach explains, "So at a very high level, there are millions and millions of people across the neurology spectrum who need this type of neuro rehabilitation, neurotherapeutic solutions, either with a therapist or without, but there are only so many therapists to go around. So there's a massive supply-demand imbalance that frankly cannot be, despite the efforts of the great therapists out there, it can never be filled without resorting to technology. And that's the exact gap that we're trying to fill in the marketplace."   "So MindMaze Therapeutics has a suite of solutions that are deployed across the whole continuum of care. So from acute care to the hospital to inpatient rehabilitation facilities, IRFs, to long-term acute care, to skilled nursing facilities, to outpatient, and all the way even patients taking the technology home. And then in that way, we're meeting the patient wherever they may happen to be. We're supporting the health system around the world. And importantly, we're giving therapy in this important neuroelastic window, which, in some studies, is the first 90 days following, say, a stroke, and in other studies, it goes all the way up to six months. And we're helping the health systems around the world scale their ability to treat even more patients at a very high and even improved rate." #MindMaze #ParkinsonsDisease #DigitalHealth #Neuroplasticity #PrecisionMedicine #Physiatry #Neurology #PhysicalTherapy #OccupationalTherapy #RehabInnovation #HealthTech MindMazeTherapeutics.com Listen to the podcast here

  6. 6d ago

    Immersive Precision Neurotherapy for Stroke and Parkinson's Rehabilitation with Zach Henderson MindMaze Therapeutics

    Zach Henderson, CEO at MindMaze Therapeutics, has designed a precision neurotherapeutic solution designed to offer a scalable, engaging and immersive platform for patients recovering from strokes or managing Parkinson's disease. The solution is deployed across the entire care continuum from hospital to the patient's home, providing high-intensity therapy during the neuroplastic window. The emphasis is on augmenting therapists' care by equipping them with tools to encourage therapy adherence and with data to deliver precise, personalized care. Zach explains, "So at a very high level, there are millions and millions of people across the neurology spectrum who need this type of neuro rehabilitation, neurotherapeutic solutions, either with a therapist or without, but there are only so many therapists to go around. So there's a massive supply-demand imbalance that frankly cannot be, despite the efforts of the great therapists out there, it can never be filled without resorting to technology. And that's the exact gap that we're trying to fill in the marketplace."   "So MindMaze Therapeutics has a suite of solutions that are deployed across the whole continuum of care. So from acute care to the hospital to inpatient rehabilitation facilities, IRFs, to long-term acute care, to skilled nursing facilities, to outpatient, and all the way even patients taking the technology home. And then in that way, we're meeting the patient wherever they may happen to be. We're supporting the health system around the world. And importantly, we're giving therapy in this important neuroelastic window, which, in some studies, is the first 90 days following, say, a stroke, and in other studies, it goes all the way up to six months. And we're helping the health systems around the world scale their ability to treat even more patients at a very high and even improved rate." #MindMaze #ParkinsonsDisease #DigitalHealth #Neuroplasticity #PrecisionMedicine #Physiatry #Neurology #PhysicalTherapy #OccupationalTherapy #RehabInnovation #HealthTech MindMazeTherapeutics.com Download the transcript here

    24 min

  7. Jun 30 ·  Bonus

    Cloud-Based Vendor-Agnostic EEG Platform Unifies and Standardizes Data with Daniele De Mari Neurogram TRANSCRIPT

    Daniele De Mari, Founder and CEO of Neurogram, points out the significant problem of non-standardized data formats in EEG (electroencephalography), compared to the universal standard used in radiology.  Neurogram has developed a hardware-agnostic, cloud-based solution that standardizes EEG data from various manufacturers, integrates with EMRs, significantly improves clinical workflows, and is accessible from any computer. With improved data security and the ability to analyze large datasets, this platform can support advances in biomarker development for neurological conditions and stimulate more clinical research and collaboration.  Daniele explains, "So the problem is not 100% on medical exams. It happens exclusively on EEG, and that makes it worse, because it doesn't happen everywhere, it's actually worse for EEG scans. So, knowing a parallel between EEG scans and radiology, every data point in radiology is DICON. So DICON is a universal file format that is standardized. I can send you a DICON over email or to your phone, WhatsApp, and you can open it on your phone. That's how universal it is. That's how open the file type is. It's compatible with EMRs. And so that's awesome. And that's one of the reasons why radiology grows so much. And EEG, it's an electroencephalogram. We have, I would say, 15 different brands around the world. In Brazil, we have seven. In the US, we have top like four or five companies, and they all export data in a different file format. So brand A has its own format, brand B has its own format, brand C, and so forth." "So we managed to be compatible with most of the brands out there, most of the EEG brands out there. We have a solution that is 100% agnostic and 100% in the cloud, which means we can read from multiple EEG devices out there. If you record in brand A, and I'm not going to say the brands in the podcast, but if you require data from brand A, brand B, brand C, all of it gets standardized into one unified system. So the physician no longer has to log into multiple devices in multiple systems, and it's all in one place. As I said, it's 100% in the cloud, so they can access from a Mac computer, which is now impossible to read EEGs from a Mac computer. Now you can do this. It's compliant. It's HIPAA compliant. We're moving towards the FDA approval process right now for the system, although we're actually selling in Brazil." #Neurogram #EEG #HealthcareIT #ClinicalNeurophysiology #DigitalHealth #HealthDataStandardization #EMRIntegration #MedicalAI #PatientSafety #HealthcareInnovation neurogram.com Listen to the podcast here

  8. Jun 30

    Cloud-Based Vendor-Agnostic EEG Platform Unifies and Standardizes Data with Daniele De Mari Neurogram

    Daniele De Mari, Founder and CEO of Neurogram, points out the significant problem of non-standardized data formats in EEG (electroencephalography), compared to the universal standard used in radiology.  Neurogram has developed a hardware-agnostic, cloud-based solution that standardizes EEG data from various manufacturers, integrates with EMRs, significantly improves clinical workflows, and is accessible from any computer. With improved data security and the ability to analyze large datasets, this platform can support advances in biomarker development for neurological conditions and stimulate more clinical research and collaboration.  Daniele explains, "So the problem is not 100% on medical exams. It happens exclusively on EEG, and that makes it worse, because it doesn't happen everywhere, it's actually worse for EEG scans. So, knowing a parallel between EEG scans and radiology, every data point in radiology is DICON. So DICON is a universal file format that is standardized. I can send you a DICON over email or to your phone, WhatsApp, and you can open it on your phone. That's how universal it is. That's how open the file type is. It's compatible with EMRs. And so that's awesome. And that's one of the reasons why radiology grows so much. And EEG, it's an electroencephalogram. We have, I would say, 15 different brands around the world. In Brazil, we have seven. In the US, we have top like four or five companies, and they all export data in a different file format. So brand A has its own format, brand B has its own format, brand C, and so forth." "So we managed to be compatible with most of the brands out there, most of the EEG brands out there. We have a solution that is 100% agnostic and 100% in the cloud, which means we can read from multiple EEG devices out there. If you record in brand A, and I'm not going to say the brands in the podcast, but if you require data from brand A, brand B, brand C, all of it gets standardized into one unified system. So the physician no longer has to log into multiple devices in multiple systems, and it's all in one place. As I said, it's 100% in the cloud, so they can access from a Mac computer, which is now impossible to read EEGs from a Mac computer. Now you can do this. It's compliant. It's HIPAA compliant. We're moving towards the FDA approval process right now for the system, although we're actually selling in Brazil." #Neurogram #EEG #HealthcareIT #ClinicalNeurophysiology #DigitalHealth #HealthDataStandardization #EMRIntegration #MedicalAI #PatientSafety #HealthcareInnovation neurogram.com Download the transcript here

    20 min
See All (2K)

4.9
out of 5
18 Ratings

About

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

Information

You Might Also Like